Author: Peter Norman, MBA, PhD
TABLES
Table 1.1. Advantages and Disadvantages of Classes of Drugs Used To Treat Type II Diabetes
Table 3.1. Global Sales in 2009 of Modified Insulins
Table 3.2. Significant KATP Channel Modulators and 2009 Sales
Table 3.3. Global Sales in 2009 of Approved DPP IV Inhibitors
Table 3.4. Global Sales in 2009 of Leading Branded Combination Products
Table 4.1. Insulin Formulations in Development
Table 4.2. PPAR Agonists in Development
Table 4.3. Other Development Products Acting on Established Targets
Table 4.4. Exenatide Formulations in Development
Table 4.5. Novel GLP-1 Analogs in Development
Table 4.6. DPP IV Inhibitors in Development
Table 4.7. SGLT2 Inhibitors in Development
Table 4.8. Glucokinase Activators in Development
Table 4.9. 11β-HSD1 Inhibitors in Development
Table 4.10. PTP1B Inhibitors in Development
Table 4.11. GPR119 Agonists in Development
Table 4.12. DGAT-1 Inhibitors in Development
Table 4.13. SCD1 Inhibitors in Development
Table 4.14. TGR5 Agonists in Development
Table 4.15. FBP Inhibitors in Development
Table 4.16. Glycogen Phosphorylase Inhibitors in Development
Table 4.17. AMPKa Modulators in Development
Table 4.18. SIRT1 Activators in Development
Table 4.19. Other Orally Active Antidiabetic Drugs in Development
Table 4.20. Other Biological Agents in Development for the Treatment of Diabetes
Table 5.1. Eli Lilly’s Development Pipeline of Diabetes Products
Table 5.2. GlaxoSmithKline’s Development Pipeline of Diabetes Products
Table 5.3. Merck’s Development Pipeline of Diabetes Products
Table 5.4. Novo Nordisk’s Development Pipeline of Diabetes Products
Table 5.5. sanofi-aventis’ Development Pipeline of Diabetes Products
Table 5.6. Takeda’s Development Pipeline of Diabetes Products
Table 5.7. Amgen’s Development Pipeline of Diabetes Products
Table 5.8. Astellas’ Development Pipeline of Diabetes Products
Table 5.9. AstraZeneca’s Development Pipeline of Diabetes Products
Table 5.10. Boehringer Ingelheim’s Development Pipeline of Diabetes Products
Table 5.11. Bristol-Myers Squibb’s Development Pipeline of Diabetes Products
Table 5.12. Novartis’ Development Pipeline of Diabetes Products
Table 5.13. Pfizer’s Development Pipeline of Diabetes Products
Table 5.14. Roche’s Development Pipeline of Diabetes Products
Table 5.15. Amylin’s Development Pipeline of Diabetes Products
Table 5.16. Arisaph’s Development Pipeline of Diabetes Products
Table 5.17. Biodel’s Development Pipeline of Diabetes Products
Table 5.18. DARA BioSciences’ Development Pipeline of Diabetes Products
Table 5.19. Diabetology’s Development Pipeline of Diabetes Products
Table 5.20. DiaMedica’s Development Pipeline of Diabetes Products
Table 5.21. Diasome’s Development Pipeline of Diabetes Products
Table 5.22. Ipsen’s Development Pipeline of Diabetes Products
Table 5.23. Metabolex’ Development Pipeline of Diabetes Products
Table 5.24. Piramal’s Development Pipeline of Diabetes Products
Table 5.25. Poxel’s Development Pipeline of Diabetes Products
Table 5.26. Theracos’ Development Pipeline of Diabetes Products
Table 5.27. TransTech Pharma’s Development Pipeline of Diabetes Products
FIGURES
Figure 1.1. Schematic of Treatment Regimen for Diagnosed Type II Diabetics
Figure 3.1. Global Diabetes Market 2009, Market Share by Therapeutic Class
Figure 3.2. Global Diabetes Market 2009, Market Share by Company
Figure 6.1. Anticipated FDA Filing Dates for Significant New Products
Figure 6.2. Forecast Share by Therapeutic Class of Global Diabetes Market in 2014